Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Jun 18;74(8):242. doi: 10.1007/s00262-025-04070-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2025

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 5 — Cisplatin combined with DEX_XCL1 promote cDC1 recruitment, activation and tumor antigen presentation in tumor tissue of prostate cancer mice. A Flow cytometric and quantitative analysis of XCR1⁺SIRPα⁻cDC1 in CD11c⁺TILs from prostate cancer tumor mice (n = 4) B Flow cytometric and quantitative analysis of ccl19 or ccl21 specific surface chemokine receptors-CCR7 and key co-stimulatory factor-CD83 on XCR1⁺SIRPα⁻cDC1 from tumors of tumor tissue of prostate cancer mice treated with cisplatin, DEX_XCL1, cisplatin combine with DEX_XCL1 or PBS treated group (NC) (n = 4). C Flow cytometric and quantitative analysis of OVA-specific MHCI epitope-SIINFEKL presentation efficiency of intratumor DCs (n = 4). D Representative flow cytometric analysis of CFSE dilution on OT-1 T cells in the tumor-draining lymph nodes of the tumor-bearing mice with CFSE-labeled naïve OT-I CD8⁺ T cells transferring (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001)